30 Participants Needed

Psilocybin for Trauma

(NWTTPS Trial)

RM
RM
Overseen ByRoss M Allison, Plant Medicine On Boarding
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: NWTraumatherapies
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This trial tests the use of psilocybin microdosing to help patients with chronic illnesses like PTSD and depression. Psilocybin, found in certain mushrooms, helps the brain form new pathways, reducing negative thoughts. This approach targets patients who don't respond well to traditional treatments. Psilocybin has shown promise as a treatment for major depressive disorder and was designated as breakthrough therapy by the FDA.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the drug psilocybin for treating trauma?

Research suggests that psilocybin, found in 'magic mushrooms', has shown promise in treating mental health issues like major depressive disorder and addiction, which are often related to trauma. While specific data on trauma is limited, the positive effects seen in these related conditions suggest potential benefits for trauma treatment.12345

Is psilocybin generally safe for humans?

Psilocybin has been studied for safety in various conditions, showing that while some people may experience challenging experiences or mild side effects, serious adverse events are rare when used in controlled settings with proper support. In studies, most side effects were mild and resolved quickly, and the risk of enduring psychological distress is low when participants are screened and supported.36789

How does the drug psilocybin differ from other treatments for trauma?

Psilocybin is unique because it is a psychedelic compound that may help treat trauma by promoting neuroplasticity (the brain's ability to change and adapt) and facilitating fear extinction, which are not typical mechanisms of action for standard PTSD treatments. Unlike many current treatments, psilocybin is administered in a few sessions and has shown potential for long-term improvements even in treatment-resistant cases.18101112

Research Team

RM

Ross M Allison, Provider

Principal Investigator

NW Therapies Trauma Unit

Eligibility Criteria

This trial is for individuals with traumatic brain injury or wounds who have chronic conditions like PTSD, depression, MS, HIV, and Long Haulers Syndrome. Participants must consent to the study and be evaluated by a psychiatrist or therapist. Those with cardiovascular complications cannot join.

Inclusion Criteria

Administrator
On Boarding Plant Medicine Specialist
Psychiatrist
See 2 more

Exclusion Criteria

I have a heart condition.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

On-boarding

Participants are onboarded into the study by a team including a Psychiatrist, Therapist, and Micro Dosing Advisor

2 weeks
Telehealth sessions

Treatment

Participants receive enhanced micro-dosing of psilocybin every other day for 5 days, then M/W/F for 8 weeks

8 weeks
Regular telehealth check-ins

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Trauma
Trial OverviewThe study tests enhanced micro-dosing of psilocybin (a compound similar to serotonin) for trauma patients. Doses range from 0.15g to 0.33g every other day and up to 1.5 grams monthly for maintenance, aiming to create new neural pathways and alleviate symptoms.
Participant Groups
4Treatment groups
Experimental Treatment
Group I: PsychiatristExperimental Treatment1 Intervention
Psychiatrist QC scaling back SSRI's replacing with psilocybin.
Group II: Plant Medicine On BoardingExperimental Treatment1 Intervention
The participant will partner with psychiatrist to reduce SSRI's and on-board psilocybin, every M/W/F with a tailored dose of plant medicine psilocybin in the enhanced micro dose levels or 0.15g. to 0.33g with a monthly dose of 1 gram to 1.5 grams. Study Status, Oversight, Study Design, Outcome Measures, Eligibility, and informed consent will all be metrics of this study.
Group III: ParticipantExperimental Treatment1 Intervention
0.15g. thru 0.33g. tailored to participant, then Monthly a 1 time dose of 1gram to 1.5 grams dose of non-synthesized plant medicine psilocybin.
Group IV: On-Boarding Plant Medicine SpecialistExperimental Treatment1 Intervention
The On-Boarding Provider will control dosage of the plant medicine via Telehealth.

Find a Clinic Near You

Who Is Running the Clinical Trial?

NWTraumatherapies

Lead Sponsor

Trials
1
Recruited
30+

World Health Organization

Collaborator

Trials
236
Recruited
1,620,000+

Findings from Research

Psilocybin, found in 'magic mushrooms', shows promise as a non-addictive alternative for treating mental health disorders like major depressive disorder and addiction, potentially addressing the urgent need for new therapies amid rising addiction and suicide rates.
Current research indicates that psilocybin may offer therapeutic benefits without the overdose risks associated with traditional mind-altering substances, suggesting a safer option for patients.
Psilocybin Therapeutic Research: The Present and Future Paradigm.Kargbo, RB.[2021]
In a study of 27 patients with moderate to severe major depressive disorder, psilocybin-assisted treatment showed significant and lasting antidepressant effects, with 75% of participants experiencing a treatment response and 58% achieving remission after 12 months.
There were no serious adverse events related to psilocybin, indicating a favorable safety profile, and participants reported meaningful personal and spiritual experiences that correlated with increased well-being, although these did not directly predict improvements in depression.
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.Gukasyan, N., Davis, AK., Barrett, FS., et al.[2022]
In a survey of 1993 individuals who experienced challenging psilocybin trips, 39% rated their experience as one of the most difficult of their lives, with 11% reporting risks of physical harm, particularly influenced by dose and lack of support.
Despite the challenges, 84% of respondents felt they benefited from the experience, suggesting that while adverse effects can occur, the overall incidence of serious psychological distress is low, especially in controlled settings.
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.Carbonaro, TM., Bradstreet, MP., Barrett, FS., et al.[2018]

References

Psilocybin Therapeutic Research: The Present and Future Paradigm. [2021]
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. [2022]
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. [2018]
The pharmacology of psilocybin. [2016]
Hallucinogenic mushrooms. [2017]
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. [2023]
The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review. [2023]
Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD. [2023]
Therapeutic use of psilocybin: Practical considerations for dosing and administration. [2022]
Psilocybin for Trauma-Related Disorders. [2022]
[Treatment with psilocybin: applications for patients with psychiatric disorders]. [2021]
Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity. [2023]